Position Statements   |   White Paper

ASGCT Releases White Paper Addressing the Value of Gene Therapy

ASGCT Staff - May 11, 2018

The American Society of Gene & Cell Therapy has issued a white paper addressing the value of current and future gene therapies approved for clinical use in the United States.

The value of gene therapy has become an increasingly prominent topic following the 2017 FDA approval of three gene therapies (including gene-modified cell therapies). Any discussion of the value of gene therapy must include the vast potential of these therapies to treat a variety of diseases, many of them rare disorders with great unmet need. ASGCT has therefore created a white paper, Addressing the Value of Gene Therapy: Enhancing Patient Access to Transformative Treatments.

The paper highlights the substantial value of gene therapy and the need to lower barriers between patients and access to approved therapies. ASGCT identifies priority solutions and recommends further exploration of additional means for stakeholders in the field to work toward maximizing the potential value of gene therapy through enhanced patient access.

Read the Full Paper

Related Articles

Position Statements

A Statement of Solidarity

ASGCT Board of Directors - June 07, 2020
Position Statements

ASGCT Statement on Germline Gene Editing Practices

ASGCT Executive Committee - November 26, 2018

Image background: Rita Elena Serda, Duncan Comprehensive Cancer Center at Baylor College of Medicine, National Cancer Institute, National Institutes of Health


ASGCT Supports NIH/RAC Recommendation

ASGCT Staff - August 30, 2018
Policy Updates

ASGCT Submits Comments on FDA Draft Guidance on Regenerative Medicine Expedited Programs

ASGCT Staff - February 19, 2018